Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia

Blood

Volumn 116, Issue 26, 2010, Pages 6018-6022

  Imagawa, Jun ^a   Harada, Yuka ^a   Shimomura, Takeshi ^b   Tanaka, Hideo ^c   Okikawa, Yoshiko ^b   Hyodo, Hideo ^a   Kimura, Akiro ^a   Harada, Hironori ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HLA DR ANTIGEN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; TRANSCRIPTION FACTOR RUNX1; VINDESINE;

ADULT; AGED; ARTICLE; BONE MARROW TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

EID: 78650660585     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-289389     Document Type: Article

References (15)

1. Latagliata R, Petti MC, Fenu S, et al. Therapyrelated myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99(3):822-824.
2. Garcia-Manero G, Kantarjian HM, Kornblau S. Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia. 2002;16(9):1888.
3. Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003;17(8):1600-1604.
4. Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001;48(suppl 1): S65-S71.
5. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59-66.
6. Harada H, Harada Y, Niimi H. Kyo T. Kimura A. Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103(6):2316-2324.
7. Ding Y, Harada Y, Imagawa J. KimuraA. Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114(25):5201-5205.
8. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 2006;20(4):635-644.
9. Zompi S, Viguie F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2002;43(2):275-280.
10. Andersen MK, Pedersen-Bjergaard J. Therapyrelated MDS and AML in acute promyelocytic leukemia. Blood. 2002;100(5):1928-1929; author reply 1929.
11. Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001;8(4):189-191.
12. Snijder S, Mellink CH, van der Lelie H. Translocation (2;11) (q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. Cancer Genet Cytogenet. 2008;180(2):149-152.
13. Park TS, Choi JR, Yoon SH, et al. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t (3; 21) (q26;q22) and RUNX1-MDS1-EVI1 fusion transcript. Cancer Genet Cytogenet. 2008;187(2):61-73.
14. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
15. Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.